811 related articles for article (PubMed ID: 7809932)
1. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
[TBL] [Abstract][Full Text] [Related]
2. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.
Imamura M; Hashino S; Kobayashi H; Kubayashi S; Hirano S; Minagawa T; Tanaka J; Fujii Y; Kobayashi M; Kasai M
Bone Marrow Transplant; 1994 Jun; 13(6):745-51. PubMed ID: 7920309
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the anti-GVHD effect of IL-2. I. Protective host-type cell populations are not induced by IL-2 treatment alone.
Abraham VS; Sykes M
Bone Marrow Transplant; 1991; 7 Suppl 1():29-32. PubMed ID: 2043882
[TBL] [Abstract][Full Text] [Related]
4. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
[TBL] [Abstract][Full Text] [Related]
5. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
Sykes M; Abraham VS; Harty MW; Pearson DA
J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
[TBL] [Abstract][Full Text] [Related]
6. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
[TBL] [Abstract][Full Text] [Related]
7. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
8. A possible association between the presence of interleukin-4-secreting cells and a reduction in the risk of acute graft-versus-host disease.
Takabayashi M; Kanamori H; Takasaki H; Yamaji S; Koharazawa H; Taguchi J; Tomita N; Fujimaki K; Fujisawa S; Maruta A; Ishigatsubo Y
Exp Hematol; 2005 Feb; 33(2):251-7. PubMed ID: 15676220
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
Ushiyama C; Hirano T; Miyajima H; Okumura K; Ovary Z; Hashimoto H
J Immunol; 1995 Mar; 154(6):2687-96. PubMed ID: 7876541
[TBL] [Abstract][Full Text] [Related]
10. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
[TBL] [Abstract][Full Text] [Related]
11. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of protection from graft-versus-host disease mortality by IL-2. III. Early reductions in donor T cell subsets and expansion of a CD3+CD4-CD8- cell population.
Abraham VS; Sachs DH; Sykes M
J Immunol; 1992 Jun; 148(12):3746-52. PubMed ID: 1534824
[TBL] [Abstract][Full Text] [Related]
13. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies.
Toren A; Barak V; Novick D; Nagler A
Cytokines Cell Mol Ther; 1997 Sep; 3(3):153-8. PubMed ID: 9426973
[TBL] [Abstract][Full Text] [Related]
14. Alloengraftment in IL-2-treated mice.
Sykes M; Pearson DA
Bone Marrow Transplant; 1992 Aug; 10(2):157-63. PubMed ID: 1525605
[TBL] [Abstract][Full Text] [Related]
15. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease.
Via CS; Rus V; Gately MK; Finkelman FD
J Immunol; 1994 Nov; 153(9):4040-7. PubMed ID: 7930611
[TBL] [Abstract][Full Text] [Related]
16. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease.
Krenger W; Snyder KM; Byon JC; Falzarano G; Ferrara JL
J Immunol; 1995 Jul; 155(2):585-93. PubMed ID: 7608537
[TBL] [Abstract][Full Text] [Related]
17. Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro.
Emmanouilides CE; Luo J; Baldwin G; Buckley D; Lau P; Lopez E; Tabibzadeh S; Yu J; Wolin M; Rigor R; Territo M; Black AC
Bone Marrow Transplant; 1996 Aug; 18(2):369-75. PubMed ID: 8864448
[TBL] [Abstract][Full Text] [Related]
18. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.
Yabe M; Yabe H; Hattori K; Shimizu T; Matsumoto M; Morimoto T; Yasuda Y; Inoue H; Kato S; Nishimura T
Bone Marrow Transplant; 1999 Jul; 24(1):29-34. PubMed ID: 10435731
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.
Murphy WJ; Welniak LA; Taub DD; Wiltrout RH; Taylor PA; Vallera DA; Kopf M; Young H; Longo DL; Blazar BR
J Clin Invest; 1998 Nov; 102(9):1742-8. PubMed ID: 9802888
[TBL] [Abstract][Full Text] [Related]
20. Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute graft-versus-host disease.
Saito K; Yagita H; Hashimoto H; Okumura K; Azuma M
Eur J Immunol; 1996 Dec; 26(12):3098-106. PubMed ID: 8977310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]